Introduction Sentinel lymph node (SLN) biopsy has long been considered as an alternative for pelvic lymphadenectomy in cervical cancer. However, the optimal strategy for applying SLN biopsy in cervical cancer remains lacking.

Methods We are performing a multicenter, randomized controlled trial to compare the two approaches for lymph node dissection in cervix cancer (PHENIX trial, ClinicalTrials.gov number, NCT02642471). We enroll patients with FIGO 2018 stage IA1 (lymphovascular space involvement), IA2, IB1, IB2 and IIA1 cervical squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma. SLN biopsy were performed at the start of surgery. The SLNs were submitted for frozen section examination and patients were triaged into the PHENIX-I (SLN-negative) or PHENIX-II (SLN-positive) cohort. In each cohort, patients were randomized in a 1:1 ratio into the experimental (SLN biopsy alone) or reference (pelvic lymphadenectomy) arm. This trial was designed with non-inferiority hypothesis and the primary endpoint is disease-free survival. Estimated sample sizes of 830 and 250 are required to fulfill the study objectives of PHENIX-I and II, respectively.

Current Trial Status Up to June 2023, 826 and 67 patients enrolled PHENIX-I and PHENIX-II cohort, respectively. Twenty-five patients were excluded due to inappropriate postoperative pathology. Among the current data, the bilateral detecting rate of SLN was 82.4%. The frozen section examination was found false-negative in 7 patients and false-positive in 3. Adjuvant therapies were administered in 47.9% patients with pathological risks. The median follow-up time reached 30 months. Neither of the cohorts showed difference in disease-free survival between the arms. The final presentation of results is expected in 2026.
and the size or number of LN metastasis is not yet reflected in both the staging system and treatment modality. The therapeutic effect of surgical resection of bulky lymph node before standard treatment has been reported in several retrospective studies. However, there are lack of well-planned randomized clinical study. Therefore, the aim of the Korean Gynecologic Oncology Group (KGOG) 1047/DEBULK trial is to investigate whether the debulking surgery of bulky or multiple LNs prior to concurrent chemoradiation therapy (CCRT) improves the survival rate in cervical cancer IIICr as diagnosed by imaging.

**Methods**
The KGOG 1047/DEBULK trial is a phase III, multi-center, randomized clinical trial of patients with bulky or multiple lymph node metastasis in cervical cancer IIICr. This study included patients with a short-axis of a pelvic or para-aortic LN ≥ 2 cm or more than 3 LNs with a short axis > 1 cm and for whom CCRT is planned. The treatment arms will randomly be allocated to undergo either CCRT (control arm) or surgical debulking of bulky or multiple LNs prior to CCRT (experimental arm). Total 234 patients will be included (117 patients per each group) within 4 years. The primary endpoint is 3-year progression free survival. The secondary endpoints are the treatment-related complications and the radiologic accuracy.

**Current Trial Status**
Twenty-two Korean institutions have confirmed their participation, and are preparing for international joint research with India, Vietnam, and Malaysia. There are currently 15 patients enrolled.

**AS04. Endometrial/Uterine corpus cancers**

**TP008/#1500**

**TRIAL IN PROGRESS: PHASE 2/3 STUDY OF NAVEMADIN AS MAINTENANCE THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER WHO RESPONDED TO CHEMOTHERAPY (ENGOT-EN21; GOG-3089)**

1Nicole Concin, 2Ugo De Giorgi, 3Toon Van Gorp, 4Jérôme Alexandre, 5Kristina Lindemann, 6Christian Marth, 7Regina Berger, 8David Cibula, 9Maria Quindos, 10Alessandra Bolognese, 11Jacob Korach, 12Christos Papadimitriou, 13Stibani Nicum, 14Dearbhaile Collins, 15Reg Myers, 16Thomas Herzog, 17Bradley Monk, 18Noelle Gillette Cliven. 1Medical University of Innsbruck, Univ-Clinic for Gynecology and Obstetrics, Innsbruck, Austria; 2University of Antwerp, Antwerp, Belgium; 3University of Navarra, Pamplona, Spain; 4Imperial College, London, UK; 5University of Copenhagen, Copenhagen, Denmark; 6Sanofi, France; 7New York University, New York, USA; 8University of Turin, Turin, Italy; 9University of Bologna, Bologna, Italy; 10University of Tampere, Tampere, Finland; 11University of Turin, Turin, Italy; 12University of Turin, Turin, Italy; 13University of Turin, Turin, Italy; 14Cork University Hospital, Department of Medical Oncology, Cork, Ireland; 15Erasmus University Rotterdam, Department of Gynecologic Oncology, Rotterdam, Netherlands; 16University of Southern California, Los Angeles, USA; 17University of Manchester, Manchester, UK; 18York University, Toronto, Canada.

**Introduction**
Mismatch repair deficient endometrial cancer (MMRd-EC) is a subtype of endometrial carcinoma which exhibits aggressive characteristics and poor prognosis. MMRd tumors are known to be highly immunogenic and of great interest for immune checkpoint inhibitor. There is lack of data regarding the efficacy of nivolumab as induction mono-therapy in completely resectable MMRd-ECs. In this regard, we suggest a window of opportunity study of induction PD-1 blockade (nivolumab) in patients with surgically resectable MMRd-EC.

**Methods**
This multi-center, non-randomized, open-label Phase II study plans to enroll 30 patients with surgically resectable MMRd-EC. Additional inclusion criteria include clinical stage I-IIC2, tumor specimen that demonstrates MMRd by immunohistochemistry or microsatellite instability as demonstrated by NGS or PCR. Exclusion criteria include multiple primary cancers, residual adverse effects of prior therapy or history of severe hypersensitivity to any antibody products. Patients will receive nivolumab at a dose of 480 mg IV, every 4 weeks as induction therapy for six cycles. Subsequently, patients will undergo surgery and/or receive adjuvant treatment following standard institutional guidelines. The primary endpoint is complete response rate of PD-1 blockade and surgery. Secondary endpoints include objective response rate, progression-free survival, overall survival, and adverse events. Correlative studies include genomic characterization of tumors, assessment of immune infiltration of tumor microenviron-ment, and serial circulating cell-free DNA and immune biomarkers.

**Current Trial Status**
Open enrollment period: Dec/2022, to Dec/2024. The Target number: 30 patients. The study intends to provide valuable insights into the efficacy and safety of nivolumab as induction therapy for surgically resectable MMRd-EC.

**TP007/#1383**

**A PHASE II STUDY OF INDUCTION PD-1 BLOCKADE (NIVOLUMAB) IN PATIENTS WITH SURGICALLY COMPLETELY RESECTABLE MISMATCH REPAIR DEFICIENT ENDOMETRIAL CANCER (NIVEC)**

1Amal Alomari, 2Jung-Yun Lee, 3Yong Jae Lee, 4Hyun-Young Cho, 5Jeong-Yeol Park, 6Yoo Young Lee, 7Jung Chul Lim. 1Yonsei University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of; 2Korea University Guro Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of; 3Samsung Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 4Asan Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 5Samsung Medical Center, Obstetrics and Gynecology, Seoul, Korea, Republic of; 6Samsung Medical Center, Obstetrics and Gynecology, Seoul, Korea, Republic of; 7Seoul St. Mary’s hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of; 8Center for Gynecologic Cancer, National Cancer Center, Department of Obstetrics and Gynecology, Goyang, Korea, Republic of.

10.1136/ijgc-2023-IGCS.469